Here’s what you should know.
1. IMM-124E showed positive effects on all levels of evaluation, including clinical parameters, tissue level parameters and immunological biomarkers.
2. Gerhard Rogler, MD, PhD, led the three stage, pre-clinical research program.
3. Researchers conducted the study in a three-stage model aimed at measuring the biological activity of IMM-124E for colitis. Dr. Rogler said the “combination of all results showed a significant and clear beneficial biological effect of IMM-124E within the model.”
4. Immuron and Dr. Rogler are moving onto the next stage of the preclinical studies.
More articles on gastroenterology:
RedHill Biopharma enrolls last patient in Bekinda phase II study: 3 notes
Olympus, Boston Scientific & more — 4 updates on GI companies
GI leader to know: Dr. John Litchfield of Palmetto Digestive Health Specialists
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.